Bart D. Maes
Roeselare, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Iptacopan in IgA Nephropathy - Final 24-Month Data.
Journal: The New England journal of medicine
Published: March 30, 2026
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy.
Journal: The New England journal of medicine
Published: November 06, 2025
Iptacopan in Patients With IgA Nephropathy From East Asia.
Journal: Kidney international reports
Published: August 19, 2025
A meta-analysis of albuminuria as a surrogate endpoint for kidney failure.
Journal: Nature medicine
Published: June 27, 2025
The prevalence of immunoglobulin A nephropathy in the European Union and the impact of the COVID-19 pandemic: an estimation approach utilizing the kidney biopsy frequency.
Journal: Clinical kidney journal
Published: December 16, 2024
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy.
Journal: The New England journal of medicine
Published: October 25, 2024
Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy.
Journal: Journal of the American Society of Nephrology : JASN
Published: September 13, 2024
Clinical Implications of Slope of GFR in Clinical Trials of CKD Progression.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: August 29, 2024
Hypouricaemia in a patient with hereditary xanthinuria type I.
Journal: Lancet (London, England)
Published: December 13, 2023
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Journal: Lancet (London, England)
Published: September 29, 2023
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.
Journal: Kidney international
Published: December 07, 2022
Last Updated: 09/26/2026